LXRX Lexicon Pharmaceuticals Inc.

-0.04  -0%
Previous Close 11.23
Open 11.23
Price To book 11.08
Market Cap 1181456493
Shares 105,581,456
Volume 309,147
Short Ratio 15.74
Av. Daily Volume 727,464

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial did not meet primary endpoint.
Type 1 Diabetes
Phase 3 data released September 9, 2016 met primary endpoint. Secondary endpoint data due May 2017. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017.
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
Phase 3 trial initiated 4Q 2016.
Type 2 Diabetes

Latest News

  1. See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
  2. ETFs with exposure to Lexicon Pharmaceuticals, Inc. : October 16, 2017
  3. News Flash: The FDA Just Approved a Breakthrough Diabetes Device
  4. Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
  5. Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211
  6. European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy
  7. Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
  8. Slashing Fair Value Estimate on Lexicon Pharmaceuticals
  9. Why Lexicon Pharmaceuticals Is Down 11% Today
  10. New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes
  11. Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin
  12. Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress
  13. Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare Conference
  14. Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting
  15. 5 of the Most Hated Biotech Stocks on the Market: Are They Buys?